Acute Myeloid Leukemia: An Ever-Changing Disease

Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C

Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Allyson Price, MPAS, PA-C, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: adprice@mdanderson.org

https://doi.org/10.6004/jadpro.2019.10.8.12 | © 2019 Harborside™




Acute myeloid leukemia is the most common form of acute leukemia in adults. In recent years, there has been robust characterization of molecular targets for drug development, leading to the U.S. Food & Drug Administration approval of numerous new treatments during 2017 and 2018. In light of these new approvals, this article provides an update for advanced practitioners on risk stratification, which is critical for guiding treatment selection.

This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners

Table of Contents

  1. Acute Myeloid Leukemia: An Ever-Changing Disease (current article)
  2. Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
  3. The Role of the Advanced Practitioner in Enhancing Outcomes
  4. Appendix: Key Information on Newly Approved AML Drugs

For access to the full length article, please sign in.

Section Seperator
Section Seperator
Section Seperator
Section Seperator
Copyright © 2010-2022 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.